Residency · Tucson, AZ
Sponsored by University of Arizona College of Medicine-Tucson
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
The New England journal of medicine · 2023 · 703 citations · Joseph Buscema
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 486 citations · Marta Crispens
NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8.
Science advances · 2023 · 459 citations · Setsuko Chambers
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 349 citations · Marta Crispens
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
The New England journal of medicine · 2023 · 405 citations · Joseph Buscema
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 148 citations · Setsuko Chambers
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 85 citations · Marta Crispens
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 55 citations · Marta Crispens